JP2014508749A - 抗浮腫治療薬を使用する黄斑浮腫の治療方法 - Google Patents

抗浮腫治療薬を使用する黄斑浮腫の治療方法 Download PDF

Info

Publication number
JP2014508749A
JP2014508749A JP2013553642A JP2013553642A JP2014508749A JP 2014508749 A JP2014508749 A JP 2014508749A JP 2013553642 A JP2013553642 A JP 2013553642A JP 2013553642 A JP2013553642 A JP 2013553642A JP 2014508749 A JP2014508749 A JP 2014508749A
Authority
JP
Japan
Prior art keywords
less
characters
months
patient
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013553642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508749A5 (https=
Inventor
アシュトン，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of JP2014508749A publication Critical patent/JP2014508749A/ja
Publication of JP2014508749A5 publication Critical patent/JP2014508749A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2013553642A 2011-02-11 2012-02-13 抗浮腫治療薬を使用する黄斑浮腫の治療方法 Pending JP2014508749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442151P 2011-02-11 2011-02-11
US61/442,151 2011-02-11
PCT/US2012/024910 WO2012109673A1 (en) 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics

Publications (2)

Publication Number Publication Date
JP2014508749A true JP2014508749A (ja) 2014-04-10
JP2014508749A5 JP2014508749A5 (https=) 2015-02-12

Family

ID=46637026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553642A Pending JP2014508749A (ja) 2011-02-11 2012-02-13 抗浮腫治療薬を使用する黄斑浮腫の治療方法

Country Status (8)

Country Link
US (1) US20120207682A1 (https=)
EP (1) EP2673049A4 (https=)
JP (1) JP2014508749A (https=)
CN (1) CN103402582A (https=)
AU (1) AU2012214146A1 (https=)
CA (1) CA2827082A1 (https=)
RU (1) RU2013138180A (https=)
WO (1) WO2012109673A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529390A (ja) * 2017-06-13 2020-10-08 アイポイント ファーマシューティカルズ，インコーポレイティドＥｙｅＰｏｉｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 生体浸食性薬物送達デバイス

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2968882B1 (en) * 2013-03-12 2021-05-19 EyePoint Pharmaceuticals US, Inc. Drug delivery device comprising silicon-based carrier particles
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
SG10201809363SA (en) * 2013-11-15 2018-11-29 Allergan Inc Methods of treatment of ocular conditions with a sustained drug delivery implant
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530964A (ja) * 2000-04-26 2003-10-21 コントロール・デリバリー・システムズ・インコーポレイテッド 除放性薬剤送達システム、使用方法、およびその製造方法
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ575950A (en) * 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530964A (ja) * 2000-04-26 2003-10-21 コントロール・デリバリー・システムズ・インコーポレイテッド 除放性薬剤送達システム、使用方法、およびその製造方法
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 138, no. 4, JPN6015043014, 2004, pages 648 - 650, ISSN: 0003183641 *
AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 147, no. 6, JPN6015043012, 2009, pages 1022 - 1030, ISSN: 0003183639 *
ARCHIVES OF OPHTHALMOLOGY, vol. 125, no. 3, JPN6015043004, 2007, pages 309 - 317, ISSN: 0003183635 *
ARCHIVES OF OPHTHALMOLOGY, vol. 128, no. 3, JPN6015043003, 2010, pages 289 - 296, ISSN: 0003183634 *
BMC OPTHALMOLOGY, vol. 6, no. 1, JPN6015043021, 2006, pages 15, ISSN: 0003183642 *
DIABETES CARE, vol. 33, no. 7, JPN6015043018, 2010, pages 1523 - 1528, ISSN: 0003183640 *
EXPERT OPINION ON DRUG DELIVERY, vol. 5, no. 9, JPN6015043016, 2008, pages 1039 - 1046, ISSN: 0003183643 *
INTERNATIONAL OPHTALMOLOGY, vol. 27, no. 5, JPN6015043009, 2007, pages 299 - 306, ISSN: 0003183637 *
OPHTHALMOLOGY, vol. 109, no. 5, JPN6015043005, 2002, pages 920 - 927, ISSN: 0003183636 *
OPHTHALMOLOGY, vol. 117, no. 7, JPN6015043007, 2010, pages 1393 - 1399, ISSN: 0003183638 *
OPHTHALMOLOGY, vol. 119, no. 1, JPN6015043006, 2012, pages 132 - 137, ISSN: 0003183644 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529390A (ja) * 2017-06-13 2020-10-08 アイポイント ファーマシューティカルズ，インコーポレイティドＥｙｅＰｏｉｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 生体浸食性薬物送達デバイス
JP7278223B2 (ja) 2017-06-13 2023-05-19 アイポイント ファーマシューティカルズ，インコーポレイティド 生体浸食性薬物送達デバイス

Also Published As

Publication number Publication date
AU2012214146A1 (en) 2013-08-29
RU2013138180A (ru) 2015-03-20
CN103402582A (zh) 2013-11-20
EP2673049A4 (en) 2015-04-08
CA2827082A1 (en) 2012-08-16
US20120207682A1 (en) 2012-08-16
EP2673049A1 (en) 2013-12-18
WO2012109673A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
JP2014508749A (ja) 抗浮腫治療薬を使用する黄斑浮腫の治療方法
Campochiaro et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial
Campochiaro et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert
Kauper et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases
Chang-Lin et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant
Jaffe et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four–week results of a multicenter randomized clinical study
Dutra Medeiros et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema
JP6171036B2 (ja) 眼球インプラントに治療薬を注入するためのシステム
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
JP2014508749A5 (https=)
KR20060085246A (ko) 경공막 전달
KR102737950B1 (ko) 안질환 치료를 위한 조성물 및 방법
EP2600920A2 (en) Subconjunctival implant for posterior segment drug delivery
TW200538135A (en) Extended therapeutic effect ocular implant treatments
CN105407896A (zh) 缓释的地塞米松在白内障手术后的炎症中的应用
US20160317438A1 (en) Injectable sustained release intraocular device
JP2010522774A (ja) 血管新生眼疾患を治療するための方法
Al Zamil Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema
EP3681448B1 (en) Device for intraocular release of a medicament
JP2011513337A (ja) 椎間板ヘルニアを治療するための方法および組成物
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
HK1142528A (en) Methods for treating neovascular ocular diseases
BR102012009316A2 (pt) Dispositivo de liberação prolongada de talidomida e uso em doenças oculares causadoras de neovascularização
HK1164761B (en) Posterior segment drug delivery

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160816